Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:IPHA

Innate Pharma 2/14/2026 Earnings Report

Innate Pharma logo
$1.46 +0.03 (+2.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 -0.03 (-2.40%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innate Pharma EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innate Pharma Revenue Results

Actual Revenue
$2.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innate Pharma Announcement Details

Quarter
Date
2/14/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Innate Pharma's Q1 2026 TU earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 TU Earnings Report

Conference Call Resources

Innate Pharma Earnings Headlines

Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference
April 23, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68275426-innate-pharma-sa-innate-pharma-to-participate-in-the-d-boral-capital-global-conference-004.htm
Innate Pharma to Participate in the D. Boral Capital Global Conference
April 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260422705960/en/innate-pharma-to-participate-in-the-d.-boral-capital-global-conference/
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
April 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260417313341/en/innate-pharma-to-present-matisse-phase-2-interim-results-of-iph5201-in-clinical-trials-plenary-session-at-aacr-2026/
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260412718494/en/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026/
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260412530712/en/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-may-21-2026/
See More Innate Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email.

About Innate Pharma

Innate Pharma (NASDAQ:IPHA) SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca. In addition to monalizumab, Innate Pharma’s pipeline includes multiple early- to late-stage candidates such as IPH5201 (anti-TIM-4) and IPH6101 (anti-IL-1RAP), which aim to broaden therapeutic options across solid tumors and hematological malignancies. These assets reflect Innate Pharma’s commitment to advancing precision immunotherapies through strategic partnerships and rigorous clinical development.

Since its inception, Innate Pharma has established a global footprint, conducting multi-center clinical trials across Europe and North America. The company’s research facilities in Marseille support a multidisciplinary team of scientists, clinicians and regulatory experts focused on biomarker-driven approaches. Through collaborations with major pharmaceutical companies, Innate Pharma leverages complementary expertise to accelerate the translation of its discovery efforts into the clinic.

Led by a management team with deep experience in biotechnology product development, Innate Pharma maintains a strategic focus on unlocking the potential of innate immunity for cancer treatment. The company’s operations benefit from a robust intellectual property portfolio and a track record of forging alliances that enhance its capacity to deliver innovative oncology solutions to patients worldwide.

View Innate Pharma Profile
Earnings Tools